Rosetta Genomics (Princeton, New Jersey) said that it and Tel Hashomer Medical (Rehovot, Israel) have won a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 13/412,020, titled, "Gene Expression Signature for Classification of Kidney Tumors."

The statement notes that the allowed patent "claims a method for distinguishing four different types of kidney cancers," a list that includes oncocytoma, clear cell renal cell carcinoma (RCC), papillary (chromaphil) RCC and chromophobe RCC in a human subject with renal cancer. The patented article is said to work via "the expression profile of a unique set of 24 microRNAs and a classifier algorithm.

The benefit of the use of the patented item can reduce the the number of unnecessary surgeries in the case of oncocytomas, but the statement also claims that new molecularly-targeted therapeutics for kidney cancer "are making accurate sub-classification of tumor type important for optimizing treatment choices and improving outcomes."

Rosetta said the impact of current limitations on diagnostic capability in renal oncocytoma was highlighted by a recent health economics outcome review kidney mass management in a study that is said to have "clearly demonstrated the adverse economic and health outcomes impact of poor pre-operative diagnosis." An analysis of the IMS LifeLink database, which boasts data on more than 60 million commercially insured patients in the U.S., showed that one in six undergoing nephrectomy for suspected renal cell cancer were subsequently identified as having benign disease.

Rosetta describes itself as the developer of " a full range of microRNA-based molecular diagnostics."